MedTrace Logo

Methotrexate in Ankylosing Spondylitis (MTX in AS)

NCT00243750 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2005-12-09

No results posted yet for this study

Summary

Assessing the efficacy and tolerability of methotrexate 15mg sc in the first month of treatment- if well tolerated methotrexate 20mg sc in the following 3 months in patients with active anklyosing spondylitis

Conditions

Interventions

DRUG

Methotrexate

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Joachim Sieper, Prof. · Charité Campus Benjamin-Franklin, Rheumatology

Study Design

Allocation
NON_RANDOMIZED
Purpose
ECT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2005-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243750 on ClinicalTrials.gov